Investigational Drug Information for Zosuquidar
✉ Email this page to a colleague
What is the development status for investigational drug Zosuquidar?
Zosuquidar is an investigational drug.
There have been 3 clinical trials for Zosuquidar.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2002.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Kanisa Pharmaceuticals, Eastern Cooperative Oncology Group, and Eli Lilly and Company.
Summary for Zosuquidar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 500 |
| WIPO Patent Applications | 309 |
| Japanese Patent Applications | 54 |
| Clinical Trial Progress | Phase 3 (2002-07-01) |
| Vendors | 0 |
Recent Clinical Trials for Zosuquidar
| Title | Sponsor | Phase |
|---|---|---|
| A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | Kanisa Pharmaceuticals | Phase 1/Phase 2 |
| Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | Kanisa Pharmaceuticals | Phase 1/Phase 2 |
| Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | Eli Lilly and Company | Phase 3 |
Clinical Trial Summary for Zosuquidar
Top disease conditions for Zosuquidar
Top clinical trial sponsors for Zosuquidar
US Patents for Zosuquidar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
